Payment overview · 2025
General Payments
$493.44
24 reported records · 3 companies
Healthcare provider profile · identity verified
Nadia Clark, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · DES MOINES, IA · NPI 1376106302
Verified facts
What the public records show
CMS Open Payments records show Nadia Clark, ARNP received $493.44 in general payments during 2025 across 24 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 45.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APTIOM as an associated drug or biological on 11 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Aptiom by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 699 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $225.58 | 45.7% | 16 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $217.27 | 44.0% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $50.59 | 10.2% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $294.46 | 22 |
| Education | $198.98 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $225.58 | 16 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $50.59 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $18.29 | 3 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 699 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | APTIOM open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 11 recipient NPIs · example record 1176658319 |
Aptiom · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
699 | 95 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gemtesa | Vibegron | 699 | 95 |
| Tramadol Hcl | Tramadol Hcl | 633 | 86 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 428 | 86 |
| Lorazepam | Lorazepam | 386 | 66 |
| Atorvastatin Calcium | Atorvastatin Calcium | 364 | 75 |
| Sertraline Hcl | Sertraline Hcl | 315 | 61 |
| Furosemide | Furosemide | 300 | 76 |
| Gabapentin | Gabapentin | 284 | 60 |
| Levothyroxine Sodium | Levothyroxine Sodium | 275 | 54 |
| Amlodipine Besylate | Amlodipine Besylate | 255 | 52 |
| Eliquis | Apixaban | 236 | 34 |
| Potassium Chloride | Potassium Chloride | 226 | 42 |
| Donepezil Hcl | Donepezil Hcl | 213 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 202 | 39 |
| Memantine Hcl | Memantine Hcl | 194 | 30 |
| Oxycodone Hcl | Oxycodone Hcl | 191 | 31 |
| Trazodone Hcl | Trazodone Hcl | 189 | 47 |
| Pregabalin | Pregabalin | 159 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 146 | 28 |
| Metformin Hcl | Metformin Hcl | 136 | 30 |
| Clonazepam | Clonazepam | 132 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 130 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 33 |
| Lisinopril | Lisinopril | 128 | 33 |
| Alprazolam | Alprazolam | 127 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 117 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 116 | 19 |
| Omeprazole | Omeprazole | 109 | 30 |
| Mirtazapine | Mirtazapine | 98 | 26 |
| Buspirone Hcl | Buspirone Hcl | 93 | 18 |
| Baclofen | Baclofen | 88 | 13 |
| Fentanyl | Fentanyl | 88 | suppressed |
| Levetiracetam | Levetiracetam | 86 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 85 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 83 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 83 | 12 |
| Losartan Potassium | Losartan Potassium | 77 | 21 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 76 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 74 | 39 |
| Simvastatin | Simvastatin | 72 | 15 |
| Bumetanide | Bumetanide | 61 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | suppressed |
| Carvedilol | Carvedilol | 60 | 17 |
| Spironolactone | Spironolactone | 59 | 13 |
| Myrbetriq | Mirabegron | 55 | suppressed |
| Lactulose | Lactulose | 52 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 52 | suppressed |
| Aripiprazole | Aripiprazole | 50 | 12 |
| Lamotrigine | Lamotrigine | 50 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 49 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 46 | 12 |
| Xarelto | Rivaroxaban | 46 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 45 | suppressed |
| Lacosamide | Lacosamide | 45 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 45 | 11 |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Jardiance | Empagliflozin | 42 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 41 | suppressed |
| Glipizide Er | Glipizide | 41 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 40 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | suppressed |
| Prednisone | Prednisone | 39 | suppressed |
| Risperidone | Risperidone | 39 | suppressed |
| Allopurinol | Allopurinol | 37 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 37 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 26 |
| Hydromorphone Hcl | Hydromorphone Hcl | 36 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 11 |
| Phenobarbital | Phenobarbital | 30 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | 13 |
| Meloxicam | Meloxicam | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 26 | 20 |
| Olanzapine | Olanzapine | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 25 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 23 | suppressed |
| Nyamyc | Nystatin | 23 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 20 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Anastrozole | Anastrozole | 20 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 20 | suppressed |
| Cephalexin | Cephalexin | 20 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 17 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 16 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 16 | 14 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 16 | 12 |
| Lidocaine Hcl | Lidocaine Hcl | 16 | 13 |
| Topiramate | Topiramate | 16 | suppressed |
| Trimethoprim | Trimethoprim | 16 | suppressed |
| Enulose | Lactulose | 15 | suppressed |
| Glucagon Emergency Kit | Glucagon | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 15 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 14 | suppressed |
| Zonisamide | Zonisamide | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Lorazepam Intensol | Lorazepam | 13 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Nystatin | Nystatin | 13 | 12 |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Perphenazine | Perphenazine | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Ssd | Silver Sulfadiazine | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $493.44 · 24 records | Otsuka America Pharmaceutical, Inc. | AUSTEDO XR, GEMTESA, REXULTI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Sumitomo Pharma America, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error